Health Care & Life Sciences » Pharmaceuticals | Durect Corp.

Durect Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
15,326.00
19,401.00
19,124.00
14,025.00
49,170.00
18,564
Cost of Goods Sold (COGS) incl. D&A
4,837.00
5,686.00
3,905.00
5,290.00
6,633.00
4,263
Gross Income
10,489.00
13,715.00
15,219.00
8,735.00
42,537.00
14,301
SG&A Expense
31,651.00
34,713.00
35,883.00
41,099.00
44,774.00
37,920
EBIT
21,162.00
20,998.00
20,664.00
32,364.00
2,237.00
23,619
Unusual Expense
-
-
-
9.00
-
-
Non Operating Income/Expense
284.00
-
237.00
-
-
-
Interest Expense
6.00
1,151.00
2,236.00
2,279.00
2,425.00
2,573
Pretax Income
21,452.00
22,110.00
22,663.00
34,509.00
3,695.00
25,322
Consolidated Net Income
21,452.00
22,110.00
22,663.00
34,509.00
3,695.00
25,322
Net Income
21,452.00
22,110.00
22,663.00
34,509.00
3,695.00
25,322
Net Income After Extraordinaries
21,452.00
22,110.00
22,663.00
34,509.00
3,695.00
25,322
Net Income Available to Common
21,452.00
22,110.00
22,663.00
34,509.00
3,695.00
25,322
EPS (Basic)
0.21
0.20
0.19
0.26
0.03
0.16
Basic Shares Outstanding
103,078.00
111,666.00
118,523.00
133,163.00
145,273.00
159,834
EPS (Diluted)
0.21
0.20
0.19
0.26
0.03
0.16
Diluted Shares Outstanding
103,078.00
111,666.00
118,523.00
133,163.00
145,273.00
159,834
EBITDA
20,604.00
20,397.00
20,239.00
31,948.00
1,800.00
23,365
Non-Operating Interest Income
-
39.00
-
143.00
967.00
870

About Durect

View Profile
Address
10260 Bubb Road
Cupertino California 95014
United States
Employees -
Website http://www.durect.com
Updated 07/08/2019
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. Its product pipeline consists of multiple investigational drug candidates in clinical development. It offers DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery; and REMOXY ER, which provides investigational extended release pain relief.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.